Comparing Pramipexole vs Requip
| Pramipexole | Requip (ropinirole) |
|
|---|
| Pramipexole | Requip (ropinirole) |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Pramipexole is a dopamine agonist (mimics the effects of the neurotransmitter dopamine) that may be used in the treatment of Parkinson's disease and Restless Legs Syndrome. It may cause spontaneous... View more |
Prescription only
Prescribed for Restless Legs Syndrome, Periodic Limb Movement Disorder, Parkinson's Disease. Requip may also be used for purposes not listed in this medication guide. |
Related suggestions Restless Legs Syndrome
Parkinson's Disease
Periodic Limb Movement Disorder
Popular comparisons
|
|||||||
| More about Pramipexole | More about Requip (ropinirole) | ||||||||
| Ratings & Reviews | |||||||||
|
Pramipexole has an average rating of 6.7 out of 10 from a total of 244 ratings on Drugs.com. 57% of reviewers reported a positive effect, while 27% reported a negative effect. |
Requip has an average rating of 5.9 out of 10 from a total of 122 ratings on Drugs.com. 47% of reviewers reported a positive effect, while 34% reported a negative effect. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||
View all Pramipexole side effects |
View all Requip side effects |
||||||||
| Drug Class | |||||||||
| Generic Availability | |||||||||
|
Lower cost generic |
Lower cost generic approved | ||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||
View all Pramipexole prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
| Dosage Forms | |||||||||
|
|
||||||||
| Brand Names | |||||||||
| Mirapex ER |
N/A |
||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||
|
8.9 hours |
6 hours |
||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | |||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||
| Drug Interactions | |||||||||
|
A total of 258 drugs are known to interact with Pramipexole:
|
A total of 307 drugs are known to interact with Requip:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||
|
|
||||||||
| Disease Interactions | |||||||||
| First Approval Date | |||||||||
|
July 01, 1997 |
September 19, 1997 |
||||||||
| WADA Class View classifications | |||||||||
|
N/A |
N/A |
||||||||
| More Information | |||||||||
| Patient Resources | |||||||||
| Professional Resources | |||||||||
| Related Treatment Guide | |||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Sinemet
Sinemet is used to treat symptoms of Parkinson's disease, such as muscle stiffness, tremors ...
Cogentin
Cogentin is used for extrapyramidal reaction, parkinson's disease
Ingrezza
Ingrezza (valbenazine) is used to treat tardive dyskinesia (TD) and chorea associated with ...
Requip
Requip is used to treat symptoms of Parkinson's disease, such as stiffness, tremors and muscle ...
Mirapex
Mirapex (pramipexole) treats the symptoms of Parkinson's disease and is also used to treat Restless ...
Rytary
Rytary is used to treat symptoms of Parkinson's disease and parkinsonism that may follow carbon ...
Azilect
Azilect (rasagiline) is used to treat the symptoms of Parkinson's disease. Learn about side ...
Crexont
Crexont (carbidopa and levodopa) is an extended-release capsule that may be used to treat symptoms ...
Exelon
Exelon (rivastigmine) is used to treat dementia caused by Alzheimer's or Parkinson's disease ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.